Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 12, No 3 (2016) THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE Abstract  PDF (Eng)  similar documents
A. V. Kryukov, D. A. Sychev, D. A. Andreev, A. V. Ryabova, N. P. Denisenko, M. A. Loskutnikov, O. I. Vinogradov, M. A. Domashenko
"... Aim. To study pharmacokinetics of apixaban in patients with atrial fibrillation and cardioembolic ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... The aim of this review is to assess the effect of genetic factors on the pharmacokinetic ..."
 
Vol 11, No 5 (2015) Practical aspects of apixaban use in clinical practice: continuing the theme Abstract  similar documents
S. N. Bel'diev
"... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..."
 
Vol 11, No 2 (2015) PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST Abstract  similar documents
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
"... Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base ..."
 
Vol 15, No 4 (2019) Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen Abstract  similar documents
A. I. Kochetkov, O. D. Ostroumova
"... . The favorable apixaban pharmacokinetic properties, consisting in low renal clearance, lack of clinically ..."
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..."
 
Vol 10, No 3 (2014) EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION Abstract  similar documents
"... European Medicines Agency approved apixaban use in cardioversion. ..."
 
Vol 11, No 6 (2015) Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events Abstract  similar documents
O. V. Shatalova
"... Aim. Pharmacoeconomic analysis of apixaban use compared to conventional therapy in patients ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
"... interactions, unpredictability of a pharmacodynamics and pharmacokinetics at certain patients) promoted search ..."
 
Vol 13, No 1 (2017) CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova
"... and apixaban in patients with non-valvular atrial fibrillation (AF) and to assess the impact of the both ..."
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
 
Vol 14, No 2 (2018) NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING Abstract  similar documents
Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov
"... . In comparison of different DOACs against each other apixaban demonstrated lower bleeding risk while patients ..."
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... (warfarin), antiplatelet therapy (acetylsalicylic acid) and novel oral anticoagulants such as apixaban ..."
 
Vol 1, No 2 (2005) PHARMACOKINETIC RESEARCHES AND PRACTICAL MEDICINE Abstract  similar documents
V. G. Belolipetskaya, Y. V. Sukhanov
"... An article gives in a comprehensive manner the main idea of pharmacokinetics, as the science about ..."
 
Vol 12, No 2 (2016) COMPARATIVE PHARMACOKINETICS AND EFFECT ON THE HEMODYNAMICS OF ORIGINAL AND GENERIC NEBIVOLOL IN HEALTHY VOLUNTEERS Abstract  similar documents
E. I. Bambysheva, K. V. Isaeva, M. M. Makhinova, D. T. Guranda, V. G. Belolipetskaya
"... . To study the pharmacokinetics and effect on hemodynamic parameters of the original and a generic nebivolol ..."
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
"... , антикоагулянтная терапия, варфарин, апиксабан, ривароксабан, дабигатран. Рациональная фармакотерапия в кардиологии ..."
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..."
 
Vol 9, No 4 (2013) COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Abstract  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
"... Indirect comparisons of new oral anticoagulants are performed with focus on their safety. Apixaban ..."
 
Vol 7, No 5 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES Abstract  similar documents
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy
"... , апиксабан. РФК 2011;7(5):628-636 Antithrombotic therapy in atrial fibrillation: recent approaches and near ..."
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
"... медицинской этики. Ключевые слова: фибрилляция предсердий, дабигатран, апиксабан, ривароксабан, риск ..."
 
Vol 13, No 1 (2017) DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT Abstract  similar documents
D. А. Napalkov, A. A. Sokolova, V. V. Fomin
"... anticoagulants, apixaban is associated with the best adherence to treatment and lowest bleeding incidence ..."
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... of efficacy and safety of apixaban in patients with AF, depending on the presence of CHD, PAD, concomitant use ..."
 
Vol 8, No 2 (2012) COMPARISON OF PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ORIGINAL AND GENERIC ENALAPRIL IN THE ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION Abstract  similar documents
O. P. Bobrova, M. M. Petrova
"... Aim. To study the pharmacokinetic, pharmacodynamic and pharmacoeconomic parameters of the original ..."
 
Vol 10, No 3 (2014) COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION Abstract  similar documents
A. V. Rudakova, V. A. Parfenov
"... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..."
 
Vol 1, No 1 (2005) ASSESSMENT OF QUALITY OF GENERICS IN CARDIOLOGY: REALITY AND POSSIBILITIES Abstract  similar documents
V. V. Yakusevich
"... safety are considered. Key words: generics, original drugs, pharmaceutical, pharmacokinetic ..."
 
Vol 12, No 2 (2016) ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? Abstract  similar documents
D. A. Napalkov, A. A. Sokolova, A. V. Rodionov
"... and safety of apixaban with these of warfarin in patients with atrial fibrillation and a history of ischemic ..."
 
Vol 13, No 6 (2017) PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS Abstract  similar documents
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin
"... – rivaroxaban and apixaban) were included into the cohort study in parallel groups. In addition to evaluate ..."
 
Vol 14, No 3 (2018) THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE Abstract  similar documents
I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... long-term anticoagulant therapy with apixaban in a full dose (5 mg b.i.d.), and the patient ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
 
Vol 15, No 4 (2019) According to the AUGUSTUS Trial Apixaban (Eliquis ® ) was Found to Be Safer than Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation with Acute Coronary Syndrome and/or Percutaneous Coronary Intervention Abstract  similar documents
Company Pfizer
 
Vol 7, No 6 (2011) DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER Abstract  similar documents
I. S. Yavelov
"... Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular ..."
 
Vol 4, No 2 (2008) EFFECT OF GENES SLCO1B1 AND MDR1 POLYMORPHISM ON ATORVASTATIN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: RESULTS OF PILOT PHARMACOGENETICS STUDY Abstract  similar documents
A. V. Semenov, D. A. Sichev, V. G. Kukes
"... Aim. To study effects of genes SLCO1B1 and MDR1 polymorphism on atorvastatin pharmacokinetics ..."
 
Vol 8, No 4 (2012) WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE Abstract  similar documents
E. N. Dankovtseva, S. L. Arkhipov, D. A. Zateyshchikov
"... Analysis of the current literature data on the use of warfarin in patients with cardioembolic ..."
 
Vol 12, No 1 (2016) Interaction of rivaroxaban with amiodarone, verapamil and diltiazem in patients with atrial fibrillation: terra incognita Abstract  similar documents
S. N. Bel'diev
"... . Последний увеличивает AUC апиксабана в 2,0 раза и, исходя из это- го, эксперты FDA включили в инструкцию к ..."
 
Vol 11, No 5 (2015) Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism Abstract  similar documents
A. V. Rudakova
"... Aim. To assess the cost-effectiveness of apixaban in the treatment and secondary prevention ..."
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... Atrial fibrillation (AF) is the most common cardiac cause of systemic embolism and cardioembolic ..."
 
Vol 9, No 3 (2013) TRUE RESISTANCE AND PSEUDORESISTANCE TO ASPIRIN Abstract  similar documents
A. I. Martynov, E. V. Akatova, I. V. Urlayeva, O. P. Nicolin
 
Vol 9, No 2 (2013) ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES Abstract  similar documents
Z. M. Safiullina, S. V. Shalaev
"... inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial ..."
 
Vol 11, No 1 (2015) ON THE SELECTION OF DRUGS DOSAGE REGIMEN Abstract  similar documents
E. N. Bochanova
"... A complex system of hemostasis regulation, insufficient data on drugs pharmacokinetics, multiple ..."
 
Vol 11, No 3 (2015) PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT Abstract  similar documents
A. V. Rudakova
"... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..."
 
Vol 12, No 5 (2016) The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin Abstract  similar documents
I. Yu. Koroleva, I. V. Kolesnichenko, V. P. Nosov, M. V. Zlobin, D. I. Abelevich
"... Aim. To study the effect of rivaroxaban compared with warfarin on the incidence of cardioembolic ..."
 
Vol 12, No 1 (2016) Features of pharmacotherapy in the elderly patients. Introduction to the problem Abstract  similar documents
E. A. Ushkalova, O. N. Tkacheva, N. K. Runikhina, N. A. Chukhareva, A. Yu. Bevz
"... Features of pharmacotherapy in the elderly patients are discussed. Data on the pharmacokinetics ..."
 
Vol 13, No 6 (2017) FUNCTIONAL STATE OF THE MICROCIRCULATION OF THE SKIN ACCORDING TO LASER DOPPLER FLOWMETRY IN PATIENTS WITH ATRIAL FIBRILLATION WHO UNDERWENT CARDIOEMBOLIC STROKE Abstract  similar documents
I. A. Zolotovskaya, I. L. Davydkin, A. A. Fedorovich, O. M. Drapkina
"... cardioembolic stroke. The comparison group (group 2, n=50) consisted of patients with paroxysmal or persistent ..."
 
Vol 14, No 3 (2018) NEW-ONSET ATRIAL FIBRILLATION IN SETTINGS OF ACUTE CORONARY SYNDROME. CURRENT ISSUES Abstract  similar documents
G. S. Galjautdinov1, I. V. Gorelkin, K. R. Ibragimova, R. R. Sadriev
 
Vol 12, No 5 (2016) Antiarrhythmic Drugs Use in Elderly Patients. Vaughan Williams Class III and IV Drugs Abstract  similar documents
E. A. Ushkalova, S. K. Zyryanov, K. E. Zatolochina, A. P. Pereverzev, N. A. Chukhareva
"... reactions (ADRs) because of age-related changes of pharmacokinetics, co-morbidity and drug interactions ..."
 
Vol 15, No 2 (2019) Cardiorenal relationships in the focus of risks of atrial fibrillation in patients after acute ST-elevated myocardial infarction (observational program FAKEL) Abstract  similar documents
I. A. Zolotovskaya, I. L. Davydkin, D. V. Duplyakov, V. A. Kokorin
"... factor (fW), left ventricular ejection fraction. Endpoint: new cases of AF, cardioembolic stroke, deaths ..."
 
Vol 3, No 5 (2007) CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC AMLODIPINE IN PATIENTS WITH MILD-TO-MODERATE ARTERIAL HYPERTENSION Abstract  similar documents
N. A. Belolipetskiy, S. N. Tolpygina, J. B. Zverkov, V. V. Pisarev, I. E. Koltunov, V. G. Belolipetskaya, S. J. Martsevich
"... and pharmacokinetic equivalency with an original amlodipine Norvasc and lower cost of therapy. ..."
 
Vol 4, No 3 (2008) ESTIMATION OF CLINICAL AND PHARMACOKINETIC EQUIVALENCE OF ORIGINAL AND GENERIC CARVEDILOLS IN PATIENTS WITH HYPERTENSION OF 1-2 GRADES Abstract  similar documents
E. I. Bambysheva, S. N. Tolpygina, D. F. Guranda, I. E. Koltunov, V. G. Belolipetskaja, S. J. Martsevich
"... clinical efficiency and pharmacokinetics similar to these of original carvedilol (DilatrendR). Generic ..."
 
Vol 13, No 4 (2017) CLINICAL ADVANTAGES OF TELMISARTAN: FEATURES OF PHARMACOKINETICS, PHARMACODYNAMICS AND EFFECTS ON THE DAILY BLOOD PRESSURE PROFILE Abstract  similar documents
O. D. Ostroumova, E. A. Smolyarchuk, O. V. Bondarec, E. E. Paleeva
"... The features of the pharmacokinetics of the angiotensin II receptor blocker telmisartan ..."
 
Vol 11, No 2 (2015) CHRONIC KIDNEY DISEASE AND CARDIOVASCULAR DISEASES: FOCUS ON ATRIAL FIBRILLATION Abstract  similar documents
V. N. Shishkova
"... Ривароксабан Апиксабан Биодоступность ≈6,5% ≈66% без пищи ≈50% во время еды увеличение средней AUC на 39 ..."
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... New oral anticoagulants that inhibit factor Xa (rivaroxaban, apixaban, edoksaban) or thrombin ..."
 
Vol 9, No 6 (2013) THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY Abstract  similar documents
A. V. Shulkin, E. N. Yakusheva, N. M. Popova
"... Апиксабан × Варфарин × + Дабигатран × Ривароксабан × Эдоксабан × Антигипертензивные средства Аллискирен ..."
 
Vol 10, No 6 (2014) THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY Abstract  similar documents
A. A. Rumyantsev, I. A. Pokataev, T. V. Kozlov, N. A. Rumyantsev
"... данной группы: дабигатрана этексилат (Прадакса), ривароксабан (Ксарелто), апиксабан (Эликвис) (табл. 3 ..."
 
Vol 13, No 5 (2017) WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT Abstract  similar documents
S. Yu. Martsevich, Y. V. Lukina
"...   of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..."
 
Vol 9, No 5 (2013) PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko
"... , апиксабан, эдокса- бан, бетриксабан, YM150). Эти препараты имеют предсказуемую фармакокинетику, что ..."
 
Vol 2, No 2 (2006) THE WAYS OF SYMPATHETIC SYSTEM OVERACTIVITY BLOCKING: RILMENIDINE VERSUS ATENOLOL Abstract  similar documents
Y. R. Kasherininov, E. K. Shavarova, A. A. Shavarov, N. V. Vachrameeva, A. N. Krutikov, E. V. Smirnova, A. O. Коnrady, E. V. Shlyakhto
"... under the curve” (AUC) for insulin and glucose were calculated. Plasma lipids, left ventricular mass ..."
 
Vol 12, No 1 (2016) Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis Abstract  similar documents
V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov
"... - ское испытание, ривароксабан, дабигатран, апиксабан, ВТЭО, новые пероральные антикоагулянты, новые ..."
 
Vol 10, No 3 (2014) OPTIMIZING THE TREATMENT OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASE WITH LERCANIDIPINE Abstract  similar documents
E. L. Trisvetova
"... to use safety and well-tolerated drugs. Pharmacological and pharmacokinetic properties of lercanidipine ..."
 
Vol 5, No 4 (2009) BISOPROLOL EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION ASSOCIATED WITH CARDIOPULMONARY DISEASES Abstract  similar documents
G. N. Gorokchovskaya, M. M. Petina
"... . Bisoprolol usage specifics caused by its pharmacokinetics and a pharmacodynamics are specially considered ..."
 
Vol 2, No 1 (2006) ARE ALL THE PROLONGED DRUG FORMULATIONS OF NIFEDIPINE THE SAME? Abstract  similar documents
V. G. Kukes, D. A. Sychev
"... action. Comparison of technological peculiarities of these formulations is given, pharmacokinetic ..."
 
Vol 13, No 1 (2017) ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY Abstract  similar documents
E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko
"... , апиксабан по сравнению с АСК при- водил к значимому снижению риска первой госпита- лизации пациентов с ФП в ..."
 
Vol 7, No 2 (2011) CONTEMPORARY SIGHT AT AMLODIPINE AND NEW DRUGS OF S-AMLODIPINE Abstract  similar documents
M. V. Leonova
"... (максимальная концентрация) 3,0 и 3,1 нг/мл, AUC (площадь под фармакокинети- ческой кривой) 151,4 и 139,7 нг×ч ..."
 
Vol 8, No 4 (2012) THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY Abstract  similar documents
M. Yu. Gilyarov
"... stroke. Int J Stroke 2008; 3: 105–116. 2. Ferro J. Cardioembolic stroke: an update. The Lancet Neurology ..."
 
Vol 2, No 4 (2006) QUALITATIVE DRUG: WHAT SHOULD IT LOOK LIKE? Abstract  similar documents
V. V. Iakusevich
"... (according to Russian regulative rules) in pharmacological equivalence may reach 5%, and in pharmacokinetic ..."
 
Vol 13, No 2 (2017) OBJECTIVE AND SUBJECTIVE FACTORS OF MEDICAL DRUG CHOICE Abstract  similar documents
E. B. Babanskaya, L. V. Menshikova
"... is insufficient. Doctors need and are interested in information on the pharmacokinetics and pharmacodynamics of MD ..."
 
Vol 13, No 5 (2017) CHRONOTHERAPY OF HYPERTENSION: CURRENT STATE OF THE SCIENTIFIC PROBLEM Abstract  similar documents
V. M. Gorbunov, E. Y. Fedorova, E. V. Platonova
"... , such as a double blind or cross-over design and comparison of the pharmacokinetics of antihypertensive drugs ..."
 
Vol 8, No 3 (2012) EFFECT OF THE ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE ON THE OXIDATIVE MODIFICATION OF SERUM PROTEINS IN PATIENTS WITH ISCHEMIC STROKE Abstract  similar documents
T. N. Khaybullin, E. Yu. Kravtsova, G. A. Martynova
"... lengths. Next in order of POM levels decreasing followed patients with cardioembolic and haemodynamic ..."
 
Vol 15, No 1 (2019) Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City Abstract  similar documents
A. A. Tuchkov, N. G. Gogolashvili, R. A. Yaskevich
"... -risk of cardioembolic strokes according to the CHA2DS2-VASc scale and had indications for OAC therapy ..."
 
Vol 15, No 1 (2019) Prognostic Value of ECG in Patients with Pulmonary Embolism Abstract  similar documents
I. S. Mullova, T. V. Pavlova, S. M. Khokhlunov, D. V. Duplyakov
"... with a sensitivity of 55% and a specificity of 33% (AUC=0.611) according to ROC-analysis. Risk of hypotension ..."
 
Vol 6, No 4 (2010) CLOPIDOGREL PHARMACOGENETICS Abstract  similar documents
A. N. Meshkov
"... концентрацию (Cmax) и площадь под кривой AUC активного метаболита на 30- 50% после нагрузочных доз 300 или 600 ..."
 
Vol 12, No 5 (2016) Randomised Clinical Trials and Observational Studies: the Ratio in the Hierarchy of Evidence of the Efficacy of Drugs Abstract  similar documents
S. Yu. Martsevich, N. P. Kutishenko
"... пероральных антикоагулянтов, появив- шихся в последнее время – дабигатран, ривароксабан или апиксабан (в ..."
 
Vol 14, No 1 (2018) THE CONTROL OF INTERNATIONAL NORMALISED RATIO IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH WARFARIN IN OUTPATIENT AND HOSPITAL SETTINGS: DATA FROM RECVASA REGISTRIES Abstract  similar documents
M. M. Loukianov, S. Yu. Martsevich, S. S. Yakushin, A. N. Vorobyev, K. G. Pereverzeva, A. V. Zagrebelnyy, V. Val. Yakusevich, V. Vl. Yakusevich, T. A. Gomova, M. N. Valiakhmetov, V. P. Mikhin, Yu. V. Maslennikova, M. A. Bichurina, L. A. Matskevich, E. N. Belova, V. G. Klyashtorny, E. V. Kudryashov, A. D. Deev, O. M. Drapkina, s. A. Boytsov
"... values, at which the risk of cardioembolic stroke and other thromboembolic complications is proven ..."
 
Vol 7, No 1 (2011) INFLUENCE OF CHRONOTHERAPY WITH DIFFERENT ANTIHYPERTENSIVE DRUGS ON CIRCADIAN BLOOD PRESSURE PATTERN Abstract  similar documents
V. M. Gorbunov, E. Yu. Fedorova, A. D. Deev, O. Yu. Isaikina, V. G. Belolipetskaya, E. A. Zhabina
"... monitoring (HBPM) throughout the study. Pharmacokinetics of verapamil (n=14, mean daily dose — 240.0±16.3 mg ..."
 
Vol 15, No 4 (2019) Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko
"... clearance in all oral anticoagulants, their pharmacokinetics changes to some extent with a decrease ..."
 
Vol 11, No 2 (2015) ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY Abstract  PDF (Eng)  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina
"... entered the Russian pharmaceutical market, among them: dabigatran, rivaroxaban and apixaban. These drugs ..."
 
Vol 12, No 4 (2016) Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation Abstract  similar documents
S. G. Kanorskii
"... ,0), что соответствовало средним показателям участников ключевых рандомизированных исследований апиксабана ..."
 
Vol 10, No 4 (2014) FEATURES OF THE CARDIOVERSION IN ATRIAL FLUTTER AND FIBRILLATION IN ERA OF NEW ANTICOAGULANTS: PRACTICAL CARDIOLOGIST VIEW Abstract  similar documents
S. A. Zenin, A. V. Fedoseenko, O. V. Kononenko, O. V. Pyataeva
"... витамина К (Вар- фарин), дабигатрана этексилат (Прадакса), апиксабан (Эликвис) и ривароксабан (Ксарелто ..."
 
Vol 7, No 1 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS Abstract  similar documents
M. Yu. Gilyarov, V. A. Sulimov
"... терапии при ФП пероральных ингибиторов Ха фак- тора апиксабана и ривароксабана. Однако апиксабан в ..."
 
Vol 10, No 6 (2014) PHARMACOEPIDEMIOLOGIC ANALYSIS OF HOSPITAL TREATMENT OF PATIENTS WITH CEREBRAL INFARCTION AND ATRIAL FIBRILLATION Abstract  similar documents
N. V. Mikheeva, O. V. Reshetko, N. V. Furman
"... инсульта у больных как с пароксизмальной, так и с постоянной формой ФП: апиксабан (класс I; уровень доказа ..."
 
Vol 11, No 4 (2015) EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME Abstract  similar documents
A. V. Rudakova, N. V. Lomakin
"... use of apixaban compared with warfarin and acetyl- salicylic acid. Ration Pharmacother Cardiol 2014 ..."
 
Vol 13, No 2 (2017) ONCE AGAIN ABOUT THE HIERARCHY OF EVIDENCES IN MEDICINE OR WHETHER IT IS POSSIBLE TO CHOOSE THE MOST EFFECTIVE AND SAFE DRUG WITH THE HELP OF OBSERVATIONAL STUDIES Abstract  similar documents
S. Y. Martsevich, Yu. V. Lukina, N. P. Kutishenko
"... день таких пре- паратов на российском рынке три: дабигатран, рива- роксабан и апиксабан. Каждый из этих ..."
 
Vol 12, No 5 (2016) Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention Abstract  similar documents
E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva
"... исследуемой выборке критическое значение для PRU составило 202 (AUC=0,664; 95%ДИ 0,531-0,796; р=0,02), для PAI ..."
 
Vol 7, No 5 (2011) CONGRESS OF EUROPEAN SOCIETY OF CARDIOLOGY IN PARIS: WHAT PRACTICAL PHYSICIAN SHOULD TAKE FOR THE NOTES Abstract  similar documents
S. Yu. Martsevich
"... - тода больным назначали либо апиксабан, новый ан- тикоагулянт, относящийся к группе ингибиторов Ха-фак ..."
 
Vol 12, No 6 (2016) NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Abstract  similar documents
article editorial
"... исследовании оценивались эффек- тивность и безопасность ривароксабана, апиксабана и дабигатрана в сравнении с ..."
 
Vol 9, No 2 (2013) CONCOR AM: NEW FIXED COMBINATION OF BISOPROLOL AND AMLODIPINE FOR EFFECTIVE BLOOD PRESSURE CONTROL Abstract  similar documents
статья Редакционная
"... ;25:1105–87. 7. Murdoch D, Heel RC. Amlodipine. A review of its pharmaco-dynamic and pharmacokinetic ..."
 
Vol 5, No 1 (2009) PROBLEM OF GENERIC REPLACEMENT: ADVANTAGES AND DISADVANTAGES Abstract  similar documents
S. N. Tolpygina, S. Yu. Martsevich
"... кривой «концентрация-время», так называемую AUC (area under curve). Считается, что 90% значений Cmax и ..."
 
Vol 6, No 5 (2010) THE CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY 2010 IN STOCKHOLM: NEWS FOR PRACTITIONERS Abstract  similar documents
S. Yu. Martsevich
"... AVERROES изучали эффективность апиксабана — принимаемого внутрь, являющегося прямым ингибитором Ха-фактора ..."
 
Vol 10, No 4 (2014) MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
E. A. Belikov, K. V. Davtyan, O. N. Tkacheva
"... » антикоагулянтные препараты (АК): ингибитор тромбина (дабигатран) и блокаторы фактора Ха (ривароксабан и апиксабан ..."
 
Vol 3, No 5 (2007) LISINOPRIL USAGE IN CARDIOLOGIC PRACTICE: DATA OF EVIDENCE BASED MEDICINE Abstract  similar documents
N. P. Kutishenko, S. J. Martsevich
"... недостаточности, остром Показатель Листрил Зестрил AUC (ч×нг/мл) 537,90±161 499,41±119,72 Cmax (нг/мл) 31,432±8 ..."
 
Vol 5, No 3 (2009) HEMODYNAMIC INSIGNIFICANT CAROTID ARTERIES STENOSIS AND RISK OF EMBOLIC STROKE IN PATIENTS WITH ISCHEMIC HEART DISEASE Abstract  similar documents
V. V. Semenova, A. N. Zakirova
"... Vasc Surg 2001;33(1):131-8. 18. Hornig C.R. Risk evaluation of anticoagulant therapy in cardioembolic ..."
 
Vol 12, No 1 (2016) Pharmacotherapy of pulmonary hypertension (according to the 2015 ESC/EAS Guidelines for the diagnosis and treatment of pulmonary hypertension) Abstract  PDF (Eng)  similar documents
E. L. Trisvetova, S. V. Gubkin
"... . Sidcharta P.N., Krähenbühl S., Dingemanse J. Pharmacokinetic and pharmacodynamic evaluation of macitentan ..."
 
Vol 12, No 5 (2016) Endothelium Protective Function of Statins in Men and Women with Coronary Atherosclerosis Abstract  similar documents
M. V. Klimushina, N. G. Gumanova, A. Ju. Gorshkov, N. E. Gavrilova, V. A. Metel'skaja, S. A. Boytsov
"... . Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fun- dam Clin Pharmacol ..."
 
Vol 6, No 4 (2010) ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS Abstract  similar documents
A. Y. Rychkov, N. Y. Khor'kova, A. A. Bliznyakov
"... . Leithauser B., Park J.W. Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the ..."
 
Vol 5, No 2 (2009) CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL Abstract  similar documents
D. A. Napalkov, E. N. Golovenko
"... AUC и Cmax рамиприлата находились в рам- ках общепринятого диапазона биоэквивалентности от 0,80 до 1 ..."
 
Vol 9, No 4 (2013) COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Abstract  similar documents
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky
"... , apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012;110(3):453-60. 17 ..."
 
Vol 12, No 2 (2016) SYSTEMATIC REVIEW AND META-ANALYSIS: PITFALLS OF METHODS Abstract  similar documents
Yu. V. Lukina, S. Yu. Martsevich, N. P. Kutishenko
"... the New Oral Antico- agulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and ..."
 
Vol 9, No 5 (2013) APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA Abstract  similar documents
D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev
"... , ривароксабан и апиксабан), которые в настоящее время показаны (по- казания, регламентированные российской ..."
 
Vol 13, No 2 (2017) APPROACHES TO ANTITHROMBOTIC THERAPY IN ELDERLY PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
E. A. Ushkalova, S. K. Zyryanov, E. V. Dumchenko
"... 2-3); дозе (МНО 2-3); НПА (TTR>70%) или апиксабан или прямой ингибитор или прямой ингибитор ..."
 
1 - 100 of 140 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)